Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MAIA Biotechnology, Inc. Common Stock (NY:MAIA)

1.510 -0.560 (-27.05%)
Official Closing Price Updated: 8:00 PM EST, Mar 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MAIA Biotechnology, Inc. Common Stock

< Previous 1 2 3 Next >
What's going on in today's session ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Which stocks are gapping on Tuesday? ↗
Via Chartmill
Which stocks are moving before the opening bell on Tuesday? ↗
Via Chartmill
News headline image
Which stocks are gapping on Monday? ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Biotech Giant MAIA Biotechnology (NYSE American: MAIA) Dives Headfirst into Crypto with Audacious Treasury Strategy
October 7, 2025 – In a move that sent ripples across both the biotechnology and cryptocurrency sectors, MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company... 
Via BreakingCrypto
Topics ETFs Economy
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars ↗
The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments. 
Via Stocktwits
News headline image
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients ↗
MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group. 
Via Benzinga
News headline image
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits 
Via News Direct
News headline image
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q2 2024 ↗
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients ↗
MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six... 
Via Benzinga
News headline image
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment
--News Direct-- 
Via News Direct
Topics Death
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market
MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market 
Via News Direct
News headline image
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024 ↗
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q4 2023 ↗
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
MAIA Biotech Completes Enrollment For Phase 2 Trial Of Its Candidate THIO To Fight Non-Small Cell Lung Cancer
--News Direct-- 
Via News Direct
News headline image
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
News headline image
Novel Therapy Shows Promising Results In On-Going Trials, Receives 3 Orphan Drug Designations From The FDA ↗
Vlad Vitoc, MD, MBA; CEO & Chairman of MAIA Biotechnology (NYSE: MAIA), was a guest on Benzinga’s All Access. MAIA is a targeted therapy immuno-oncology company focused on developing and... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Wipro Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Wipro Limited (NYSE: WIT) rose sharply during Friday’s session after the company reported third-quarter financial results, issued guidance and declared an interim dividend. Wipro shares... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.